MOLLICA, VERONICA
MOLLICA, VERONICA
CENTRO INTERDIPARTIMENTALE ALMA MATER INSTITUTE ON HEALTHY PLANET
Assegnisti
A brand-new CAR for macrophages: Is it time to fire up the engines of a new era for the treatment of renal cell carcinoma?
2021 Massari F.; Rizzo A.; Mollica V.; Santoni M.
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor.
2018 Mollica V, Di Nunno V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy
2022 Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss.
2019 Di Nunno V, Mollica V, Brunelli M, Gatto L, Schiavina R, Fiorentino M, Santoni M, Montironi R, Caliò A, Eccher A, Milella M, Martignoni G, Brunocilla E, Massari F
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents
2022 Rizzo A.; Oderda M.; Mollica V.; Merler S.; Morelli F.; Fragomeno B.; Taveri E.; Sorgentoni G.; Santoni M.; Massari F.
A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34
2021 Ricci C.; Franceschini T.; Giunchi F.; Borsato M.; Mollica V.; Massari F.; Fiorentino M.
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study
2021 Massari F.; Di Nunno V.; Guida A.; Costa Silva C.A.; Derosa L.; Mollica V.; Colomba E.; Brandi G.; Albiges L.
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study
2021 Massari, Francesco; Di Nunno, Vincenzo; Guida, Annalisa; Costa Silva, Carolina Alves; Derosa, Lisa; Mollica, Veronica; Colomba, Emeline; Brandi, Giovanni; Albiges, Laurence
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma
2021 Rizzo A.; Mollica V.; Massari F.
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma
2021 Rizzo, A; Mollica, V; Massari, F
Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma
2021 Mollica, V; Rizzo, A; Massari, F
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
2022 Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; Myint Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F.
Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients?
2019 Di Nunno, V.; Mollica, V.; Gatto, L.; Santoni, M.; Sorgentoni, G.; Battelli, N.; Massari, F.
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF?
2021 Mollica V.; Rizzo A.; Di Nunno V.; Santoni M.; Cheng L.; Lopez-Beltran A.; Scarpelli M.; Cimadamore A.; Montironi R.; Massari F.
Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials
2019 Massari F.; Di Nunno V.; Mollica V.; Graham J.; Gatto L.; Heng D.
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System
2022 Raschi E.; Fusaroli M.; Giunchi V.; Repaci A.; Pelusi C.; Mollica V.; Massari F.; Ardizzoni A.; Poluzzi E.; Pagotto U.; Di Dalmazi G.
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer
2020 Mollica V.; Di Nunno V.; Santoni M.; Cimadamore A.; Scarpelli M.; Lopez-Beltran A.; Cheng L.; Mariani C.; Battelli N.; Montironi R.; Massari F.
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt
2021 Mollica V.; Marchetti A.; Rosellini M.; Nuvola G.; Rizzo A.; Santoni M.; Cimadamore A.; Montironi R.; Massari F.
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma
2021 Marchetti A.; Rosellini M.; Rizzo A.; Mollica V.; Battelli N.; Massari F.; Santoni M.
An update on immunotherapy in uro-oncology
2021 Cimadamore A.; Rizzo A.; Mollica V.; Massari F.; Lopez-Beltran A.; Scarpelli M.; Cheng L.; Santoni M.; Montironi R.
Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
---|---|---|---|---|---|---|
A brand-new CAR for macrophages: Is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? | Massari F.; Rizzo A.; Mollica V.; Santoni M. | 2021-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. | Mollica V, Di Nunno V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E,... Ardizzoni A, Massari F | 2018-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy | Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa...; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco | 2022-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. | Di Nunno V, Mollica V, Brunelli M, Gatto L, Schiavina R, Fiorentino M, Santoni M, Montironi R, Ca...liò A, Eccher A, Milella M, Martignoni G, Brunocilla E, Massari F | 2019-01-01 | MOLECULAR DIAGNOSIS & THERAPY | - | 1.01 Articolo in rivista | - |
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents | Rizzo A.; Oderda M.; Mollica V.; Merler S.; Morelli F.; Fragomeno B.; Taveri E.; Sorgentoni G.; S...antoni M.; Massari F. | 2022-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34 | Ricci C.; Franceschini T.; Giunchi F.; Borsato M.; Mollica V.; Massari F.; Fiorentino M. | 2021-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study | Massari F.; Di Nunno V.; Guida A.; Costa Silva C.A.; Derosa L.; Mollica V.; Colomba E.; Brandi G....; Albiges L. | 2021-01-01 | CLINICAL GENITOURINARY CANCER | - | 1.01 Articolo in rivista | - |
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study | Massari, Francesco; Di Nunno, Vincenzo; Guida, Annalisa; Costa Silva, Carolina Alves; Derosa, Lis...a; Mollica, Veronica; Colomba, Emeline; Brandi, Giovanni; Albiges, Laurence | 2021-01-01 | CLINICAL GENITOURINARY CANCER | - | 1.01 Articolo in rivista | - |
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma | Rizzo A.; Mollica V.; Massari F. | 2021-01-01 | THE LANCET ONCOLOGY | - | 1.01 Articolo in rivista | - |
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma | Rizzo, A; Mollica, V; Massari, F | 2021-01-01 | THE LANCET ONCOLOGY | - | 1.01 Articolo in rivista | - |
Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma | Mollica, V; Rizzo, A; Massari, F | 2021-01-01 | NEW ENGLAND JOURNAL OF MEDICINE | - | 1.01 Articolo in rivista | - |
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study | Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; My...int Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | - |
Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? | Di Nunno, V.; Mollica, V.; Gatto, L.; Santoni, M.; Sorgentoni, G.; Battelli, N.; Massari, F. | 2019-01-01 | ANNALS OF TRANSLATIONAL MEDICINE | - | 1.01 Articolo in rivista | - |
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? | Mollica V.; Rizzo A.; Di Nunno V.; Santoni M.; Cheng L.; Lopez-Beltran A.; Scarpelli M.; Cimadamo...re A.; Montironi R.; Massari F. | 2021-01-01 | TRANSLATIONAL ANDROLOGY AND UROLOGY | - | 1.01 Articolo in rivista | - |
Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials | Massari F.; Di Nunno V.; Mollica V.; Graham J.; Gatto L.; Heng D. | 2019-01-01 | CLINICAL GENITOURINARY CANCER | - | 1.01 Articolo in rivista | - |
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System | Raschi E.; Fusaroli M.; Giunchi V.; Repaci A.; Pelusi C.; Mollica V.; Massari F.; Ardizzoni A.; P...oluzzi E.; Pagotto U.; Di Dalmazi G. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-04610-v2 (2).pdf |
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer | Mollica V.; Di Nunno V.; Santoni M.; Cimadamore A.; Scarpelli M.; Lopez-Beltran A.; Cheng L.; Mar...iani C.; Battelli N.; Montironi R.; Massari F. | 2020-01-01 | EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | - | 1.01 Articolo in rivista | - |
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt | Mollica V.; Marchetti A.; Rosellini M.; Nuvola G.; Rizzo A.; Santoni M.; Cimadamore A.; Montironi... R.; Massari F. | 2021-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | - |
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma | Marchetti A.; Rosellini M.; Rizzo A.; Mollica V.; Battelli N.; Massari F.; Santoni M. | 2021-01-01 | EXPERT OPINION ON PHARMACOTHERAPY | - | 1.01 Articolo in rivista | - |
An update on immunotherapy in uro-oncology | Cimadamore A.; Rizzo A.; Mollica V.; Massari F.; Lopez-Beltran A.; Scarpelli M.; Cheng L.; Santon...i M.; Montironi R. | 2021-01-01 | EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT | - | 1.01 Articolo in rivista | - |